Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis.
Adrenergic beta-Antagonists
/ administration & dosage
Age Factors
Aged
Angiotensin Receptor Antagonists
/ administration & dosage
Angiotensin-Converting Enzyme Inhibitors
/ administration & dosage
Blood Pressure
/ drug effects
Body Weight
Cohort Studies
Female
Heart Failure
/ drug therapy
Heart Rate
/ drug effects
Hospitals, University
Humans
Kidney Function Tests
Male
Multivariate Analysis
Sex Characteristics
Stroke Volume
/ drug effects
Sweden
HFrEF
Heart failure
Sex differences
Target dose
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
23
06
2019
accepted:
10
10
2019
pubmed:
4
1
2020
medline:
1
12
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
The aims of this study were to examine sex differences in a heart failure population with regards to treatment and patient characteristics and to investigate the impact of sex on achieved doses of heart failure medications. A total of 1924 patients with heart failure in a regional hospital were analysed, 622 patients had ejection fraction ≤ 40% of which 30% were women. In patients with reduced ejection fraction, women were older (79 ± 11 vs. 74 ± 12 years, P < 0.001), had lower body weight (70 ± 17 vs. 86 ± 18 kg, P < 0.001), lower estimated glomerular filtration rate (eGFR) (49 ± 24 vs. 71 ± 30 ml/min, P < 0.001) and received lower doses of heart failure medications than men. Multivariable linear regression on patients with reduced ejection fraction showed that sex was not associated with achieved dose of any heart failure medication. For angiotensin-converting enzyme inhibitors and angiotensin receptor blockers associated factors were eGFR, systolic blood pressure, age, ejection fraction, and heart rate. For beta-blockers associated factors were body weight, atrial fibrillation and age. For mineralocorticoid receptor antagonists associated factors were eGFR, serum potassium, age, systolic blood pressure, ejection fraction and heart rate. Women with heart failure and reduced ejection fraction were prescribed lower doses of heart failure medications, were older, had worse renal function, and lower body weight than men. Sex was not independently associated with achieved doses of heart failure medications, instead age, renal function and body weight explained the differences in treatment.
Identifiants
pubmed: 31897534
doi: 10.1007/s00228-019-02782-2
pii: 10.1007/s00228-019-02782-2
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-546Subventions
Organisme : Heart foundation of northern Sweden
ID : 2017
Références
Eur J Heart Fail. 2017 Jun;19(6):768-778
pubmed: 28244205
Int J Cardiol. 2018 Mar 15;255:145-151
pubmed: 29425552
J Am Coll Cardiol. 2019 Jan 8;73(1):29-40
pubmed: 30621948
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 1991 Aug 1;325(5):293-302
pubmed: 2057034
Eur J Heart Fail. 2007 Dec;9(12):1205-11
pubmed: 18023249
Lancet. 2003 Sep 6;362(9386):759-66
pubmed: 13678868
Clin Pharmacokinet. 2009;48(3):143-57
pubmed: 19385708
Eur J Heart Fail. 2016 May;18(5):503-11
pubmed: 26869252
N Engl J Med. 2011 Jan 6;364(1):11-21
pubmed: 21073363
Heart. 2008 Mar;94(3):e10
pubmed: 17575332
Eur J Heart Fail. 2013 Sep;15(9):995-1002
pubmed: 23645498
Eur J Heart Fail. 2017 Dec;19(12):1574-1585
pubmed: 28386917
Eur J Heart Fail. 2009 Mar;11(3):299-303
pubmed: 19158153
ESC Heart Fail. 2018 Apr;5(2):337-343
pubmed: 29345425
Lancet. 1999 Jan 2;353(9146):9-13
pubmed: 10023943
JAMA Cardiol. 2018 Oct 1;3(10):1011-1019
pubmed: 30140928
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
Pharmacol Res. 2007 Feb;55(2):81-95
pubmed: 17129734
N Engl J Med. 2001 Dec 6;345(23):1667-75
pubmed: 11759645
Cardiovasc Ther. 2018 Oct;36(5):e12459
pubmed: 30019390
Eur J Heart Fail. 2004 Oct;6(6):769-79
pubmed: 15542415
Circulation. 2002 Oct 22;106(17):2194-9
pubmed: 12390947
Eur J Heart Fail. 2018 Sep;20(9):1326-1334
pubmed: 29578280
Rev Port Cardiol. 2018 Jun;37(6):491-496
pubmed: 29779951
Eur J Heart Fail. 2016 May;18(5):514-22
pubmed: 27095461
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
Am J Cardiol. 2009 Jul 1;104(1):107-15
pubmed: 19576329
Lancet. 1999 Jun 12;353(9169):2001-7
pubmed: 10376614
JACC Cardiovasc Imaging. 2018 Jan;11(1):1-11
pubmed: 28917679
Int J Cardiol. 2017 Apr 1;232:216-221
pubmed: 28111054
Eur Heart J. 2012 Jul;33(14):1734-41
pubmed: 22507977
J Am Coll Cardiol. 2018 May 8;71(18):1960-1969
pubmed: 29724348
Eur J Heart Fail. 2013 Jul;15(7):808-17
pubmed: 23537547